Albers G W, Simon L T, Hamik A, Peroutka S J
Headache. 1989 Apr;29(4):215-8. doi: 10.1111/j.1526-4610.1989.hed22904215.x.
We conducted a randomized open-labeled study of nifedipine versus propranolol for the initial prophylaxis of migraine. Propranolol was effective in 67% of patients (12/18) and well tolerated. Nifedipine was effective in only 30% of patients (6/20). The lack of overall efficacy of nifedipine was attributable to a high incidence of side effects, including an unusual symptom complex resembling erythromelalgia. These side effects led 45% (9/20) of the nifedipine patients to withdraw from the study within two weeks. By contrast, no patient (0/18) withdrew from the study within the first 2 weeks of propranolol therapy. We conclude that nifedipine is not an agent of first choice for the prophylaxis of migraine.
我们进行了一项硝苯地平与普萘洛尔用于偏头痛初始预防的随机开放标签研究。普萘洛尔在67%的患者（12/18）中有效且耐受性良好。硝苯地平仅在30%的患者（6/20）中有效。硝苯地平总体疗效欠佳归因于副作用发生率高，包括一种类似红斑性肢痛症的异常症状复合体。这些副作用导致45%（9/20）服用硝苯地平的患者在两周内退出研究。相比之下，在普萘洛尔治疗的前两周内，没有患者（0/18）退出研究。我们得出结论，硝苯地平不是预防偏头痛的首选药物。
